Passage Bio Rises on Promising Phase 2 Data for Gene Therapy

Passage Bio’s gene therapy candidate, PBFT02, slowed brain atrophy by more than 90% compared to the natural progression of frontotemporal dementia (FTD), a significant development for the neurodegenerative disease that currently has no approved treatments. The company's stock surged on the news.

"These results represent a major step forward for patients with FTD, offering the potential to meaningfully alter the course of this devastating disease," said Mark Forman, M.D., Chief Medical Officer at Passage Bio. "We are highly encouraged by the data and look forward to discussing the next steps with regulatory authorities."

The updated interim data from the Phase 1/2 upliFT-D trial, presented on April 20, 2026, showed that PBFT02 administration resulted in a median 0.2% increase in brain volume at six months, compared to an expected 2.3% decline in a natural history cohort. Additionally, plasma neurofilament light chain (NfL) levels, a key biomarker for neurodegeneration, remained stable in treated patients.

The positive data provides a much-needed boost for Passage Bio and its gene therapy platform. For investors, this de-risks the clinical path for PBFT02 and increases the probability of an eventual Biologics License Application (BLA) filing. The company has a cash runway through 2028 to fund further development.

Competitive Landscape

Frontotemporal dementia is a competitive area in neurodegenerative disease research. While Passage Bio's results are promising, it faces competition from other companies developing treatments for FTD, including Alector (ALEC) and Denali Therapeutics (DNLI). Alector's lecanemab is in late-stage trials, though it targets a different pathway. The market for FTD treatments is estimated to be over $1 billion annually.

Next Steps

Passage Bio plans to engage with the FDA in the second half of 2026 to discuss the registration path for PBFT02. The company will also present further data from the upliFT-D trial at an upcoming medical conference.

This article is for informational purposes only and does not constitute investment advice.